BioLab contests inspection reports on Rockdale Co. chemical plant
The fire pushed a plume of chlorine gas into the air, causing evacuations. A shelter-in-place order was in effect for nearly a month.
Occupational Safety and Health Administration inspectors cited the company with six violations in April of this year.
One explanation said the fire started because '…hazardous chemicals such as, but not limited to, Trichloroisocyanuric acid, (TCCA), 99% Sodium Dichloroisocyanurate (DCCA), and Bromochloro-5,5-dimethylimidazolidine-2,4-dione (BCDMH) were not stored properly.'
[DOWNLOAD: Free WSB-TV News app for alerts as news breaks]
In May, the company said it would stop manufacturing chemicals at its Conyers facility but said distribution is still operational there.
'We are still under the impression there are still poisonous chemicals there, and that is the problem,' Porchse Miller told Channel 2's Courtney Francisco.
Miller is one of those neighbors suing BioLab, Inc. The Rockdale County Government is suing as well.
'If they have a distribution site, there got to be chemicals still there,' said Miller.
County leaders declined to comment due to pending litigation.
RELATED STORIES:
BioLab to close Rockdale County facility at center of chemical fire
'Treat it more seriously:' Rockdale County man says BioLab fire made him sick
Residents of Rockdale County demand answers after BioLab chemical fire
I asked BioLab, Inc. if it had changed how it stores chemicals. A spokesperson said he cannot comment on that at the time.
Federal records show BioLab, Inc. contested all six of the code violations inspectors cited it with in April.
If a company challenges results within 15 days, it can get a hearing in front of the Occupational Safety and Health Review Commission.
Channel 2 is waiting for the Department of Labor to confirm that BioLab, Inc. met that deadline.
[SIGN UP: WSB-TV Daily Headlines Newsletter]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Munchkin Revolutionizes Breastfeeding Support with Groundbreaking Innovation Backed by New Clinical Research
Coinciding with National Breastfeeding Awareness Month, new U.S. clinical research study shows 87% of moms using Munchkin's Flow Nipple Shield+ maintained breastfeeding through 12 months, more than doubling national success rates LOS ANGELES, August 04, 2025--(BUSINESS WIRE)--Munchkin Inc. ("Munchkin"), the most loved baby lifestyle brand in the world, owned by WHY Brands Inc. ("WHY"), today announced in conjunction with National Breastfeeding Awareness Month and World Breastfeeding Week, the completion of new groundbreaking clinical research that supports how Munchkin's Flow Nipple Shield+ is changing lives, empowering breastfeeding journeys and helping moms achieve their nursing goals with unprecedented success. According to Munchkin's recently completed U.S. clinical research study* of approximately 300 moms, the Flow Nipple Shield+ achieved remarkable results and showcased a paradigm shift in breastfeeding support, including: 87% of mothers continued breastfeeding at 12 months – more than double the national U.S. average of 39.5%** 98% met or exceeded their breastfeeding goals 77% reported increased confidence in their feeding journey after the first month, which is a critical point in time for self-assurance "Flow Nipple Shield+ represents a significant breakthrough in maternal health technology," says Dr. Mona Amin, Board Certified Pediatrician and International Board-Certified Lactation Consultant. "By removing the guesswork and offering real-time reassurance, it's a powerful tool to build confidence and strengthen mothers' trust in their own abilities while delivering measurable impact on breastfeeding success rates. This innovation could help reshape national maternal health outcomes by making a meaningful difference for families wanting to continue their breastfeeding journey." What sets this innovation apart is its first-to-market visual confirmation technology. Flow Nipple Shield+ features a unique channel that allows parents to actually see milk transfer during feeding – addressing one of the most common anxieties new mothers face. Made with 100% food-grade silicone and packaged in a convenient travel-friendly steam sterilizer case, Flow Nipple Shield+ is designed to support better latch, confirm milk transfer and reduce postpartum stress. "We know that feeding doesn't look the same for everyone and that's okay," said Kristin Pagano, GM Infant Nutrition at Munchkin and mom of two. "The Flow Nipple Shield+ was created to offer compassionate, judgement-free support for parents navigating the ups and downs of feeding. This month, we're proud to make it even more accessible because every parent deserves the right to feel confident, capable and supported in how they nourish their baby." Beyond individual families, Munchkin is committed to making a broader impact. The company has donated more than $100,000 worth of Flow Nipple Shield+ units to WIC (Special Supplemental Nutrition Program for Women, Infants, and Children) chapters throughout the U.S. this year ensuring that underserved families across the country have access to this game-changing support. WIC is a division of the USDA's Food & Nutrition Services that provides breastfeeding support, touching more than 43% of births in the U.S. with its services. The Munchkin Flow Nipple Shield+ Starter Kits (shield, cleaning syringe, and travel case) retails for $39.99 at Walmart, Target and Amazon. This August, Munchkin is making it even more accessible by offering a FREE Flow Replacement Kit (brand-new nipple shield and a travel case that doubles as a steam sterilizer) with every Flow Nipple Shield+ purchase. To learn more about Munchkin and first account testimonials from moms using Flow, please visit or follow us on Facebook and Instagram. *Completed clinical trial of approximately 300 U.S. moms, Munchkin Inc. x Emmes, Evaluating the Efficacy and User Satisfaction of Flow, August 2023-July 2025.**According to data from the Centers for Disease Control and Prevention (CDC), the national U.S. average of mothers continuing to breastfeed at 12 months for infants born in 2021 was 39.5%. Source: HERE. About Munchkin Inc. For more than 30 years, Munchkin Inc., the baby lifestyle brand owned by WHY Brands Inc, has produced innovative products and functional gear for children and their caregivers. Munchkin has 350+ patents to date, and more than 250 international product and brand design awards. Munchkin products are sold in more than 50 countries and have received over 1.45 million five-star reviews. Munchkin has been awarded Great Place to Work for four consecutive years and is recognized as a 2024 Best Places to Work by Built In. Munchkin has been honored on Fast Company's annual "Brands That Matter" list for two consecutive years, including 2024, and ranked number eight on Fortune's list of "Most Innovative Companies" in 2023. As the only baby brand in the United Nations Global Compact, the company prioritizes corporate social responsibility with commitments to environmental protection and animal welfare, which are highlighted in its annual Sustainability Report. Learn more at and About WHY Brands Inc. WHY is a portfolio of brands that invent, develop, and design creative products across an array of categories. With every new idea and undertaking, we ask and end with WHY. That spirit of inquiry drives our commitment to innovation, highlighted by 350+ patents to date. We believe great ideas and next-generation design can be lifechanging. WHY's portfolio includes baby lifestyle brand Munchkin and Curio Home Goods. Learn more at View source version on Contacts Media Contact flowpr@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 minutes ago
- Yahoo
Neutra Corp's Subsidiary, Neutra Life Sciences, Expands Rapidly With New Joint Venture Partnerships
HOUSTON, TX - August 4, 2025 (NEWMEDIAWIRE) - Neutra Corp (OTC: NTRR) is hitting its stride with the purposeful growth in the clinical research industry with Neutra Life Sciences. Since the successful launch of its Site Management Organization (SMO), Neutra Life Sciences has strategically positioned itself for significant growth in the latter part of 2025 and the beginning of 2026. Neutra Life Sciences has solidified its multi-specialty platform by securing another suite of Joint Venture Partnerships. These new joint venture sites will be in the onboarding process: Podiatry Epic Foot & Ankle Centers ( Radiation Oncology Aspire Hospital Cancer Centers ( Dermatology Radiant Dermatology & Aesthetics Clinic ( Expanding into more specialties gives Neutra Life Sciences a significant advantage over other organizations in the space. This diversification in medical specialties allows NLS to serve a broader patient population and meet increasing demands in clinical research. Looking ahead, Neutra Life Sciences plans to continue expanding into additional specialties, further enhancing its ability to support Contract Research Organizations (CROs) and Sponsors with a wider array of clinical indications. This strategic growth enables the company to play a critical role in accelerating the development of innovative treatments across a broader spectrum of therapeutic areas. "Our growth reflects the increasing demand for high-quality, integrated clinical research solutions," said Sydney Jim, President and CEO of Neutra Corp. "By aligning with established private practices and opening these new specialized sites, we are not only expanding our service offerings but also fostering innovation in patient care and research." Neutra Life Sciences remains focused on building a robust network of clinical research sites, delivering exceptional services to its partners, and advancing its mission to improve health outcomes through cutting-edge collaboration. For more information about the role of clinical research sites in advancing medicine, or to learn how to participate in a clinical trial, please contact Neutra Life Sciences via phone 281-598-0200 or email at info@ Neutra has made the strategic decision to divest its subsidiary, VIVIS Corporation, a hemp-based cannabis entity, as part of a broader shift toward long-term growth in the life sciences sector. This transition reflects the company's renewed focus on advancing its clinical research capabilities through its newly launched site management organization (SMO). By reallocating resources and leadership attention to the SMO business, Neutra aims to support high-quality clinical trials and expand its presence in the evolving healthcare and biotechnology landscape. This move underscores the company's commitment to innovation and delivering value in areas with greater regulatory stability and long-term market potential. About Neutra Corp Neutra Corp is a health and wellness company dedicated to advancing life sciences, clinical research, and innovative consumer health solutions. With a diversified portfolio, Neutra Corp focuses on life sciences technology, clinical research, and high-quality wellness products designed to support overall health and well-being. Committed to empowering individuals with the tools and knowledge needed to make informed healthcare decisions, Neutra Corp integrates cutting-edge research with real-world applications. Its expansion into life sciences and clinical research reinforces its mission to drive innovation in healthcare, while its wellness product line provides natural solutions for consumers seeking alternative wellness options. Through strategic acquisitions and partnerships, Neutra Corp continues to grow its impact in the life sciences and health sectors, bridging the gap between research, technology, and consumer wellness. For investing, information and performance data, please visit Notice Regarding Forward-Looking Statements Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, a description of anyone's past success, either financial or strategic, is no guarantee of success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof. View the original release on Sign in to access your portfolio
Yahoo
11 minutes ago
- Yahoo
Hims & Hers Q2 2025: What You Need to Know Ahead of Earnings
Hims & Hers Health (NYSE:HIMS) reports Q2 2025 earnings after U.S. markets close on Monday, August 4. Analysts expect revenue of around $552 million, up 75% YoY, and adjusted EPS near $0.15, roughly up 15% YoY. Despite the volatility, shares are up 154% YTD, pushing the forward P/E to roughly 57. Subscriber growth remains the core engine investors care about. Subscribers increased 38% in Q1, reaching 2.4 million. Weight-loss GLP-1 offerings are a swing factor, but Novo Nordisk (NYSE:NVO) ended its partnership on 23 Jun 2025, citing illegal mass compounding and deceptive marketing, which sent Hims down 30%. Analysts estimate that up to half of Hims' projected weight-loss revenue could be at risk. Investors need clarity on FDA scrutiny, formulary access, and whether compounded semaglutide margins can hold. Marketing spend, revenue per average user, and progress on the ZAVA integration will also be closely watched. Management guides FY25 revenue of $2.32.4 billion and low-teens EBITDA margins. Any uplift to those guides or clean regulatory commentary could keep momentum intact. But with valuation stretched, even a top-line beat may disappoint if churn ticks up or compliance costs bite. Q2 will test whether the telehealth disrupter can scale responsibly before regulators step in. This article first appeared on GuruFocus. Sign in to access your portfolio
